BePharBel Manufacturing SA

What we do: BePharBel Manufacturing is a Contract and Development Manufacturing Organization (CDMO) offering an integrated end-to-end solution for the development and manufacturing of pharmaceutical products and medical devices under European GMP standards. We specialize in the formulation and production of both sterile and non-sterile medicines for human and animal health, covering more than 10 different dosage forms such as injectables, tablets, creams, nasal sprays, and powders. Our services span from R&D and analytical development to clinical and commercial production, packaging, and regulatory support. We also act as a Marketing Authorisation Holder for a portfolio of prescription, over-the-counter, and food supplement products, primarily in ophthalmology and dermatology. Our innovative MMCR platform enables the development of controlled-release syrups, a breakthrough for patients with swallowing difficulties.

Where we are located: Our headquarters are in Courcelles, Belgium, at Rue du Luxembourg 13, 6180. This central location supports our operations and partnerships across Belgium and Europe.

Short history: Founded in 2012 by experienced professionals in pharmaceutical development, BePharBel Manufacturing has grown into a trusted partner for pharma companies seeking efficient, high-quality solutions. Over the years, we have strengthened our expertise in formulation, manufacturing, and regulatory compliance, serving more than 10 dosage forms and producing over 40 finished products.

Organization & culture: With around 70 employees, BePharBel Manufacturing combines a mid-sized structure with a strong commitment to quality, flexibility, innovation, and transparency. Our teams are dedicated to building long-term partnerships and supporting clients from concept to market launch. We value pragmatism, responsiveness, and a collaborative approach to problem-solving.

Recent developments: BePharBel has recently launched its patented MMCR technology, enabling controlled-release syrup development—a significant innovation for paediatric and elderly patients. This advancement highlights our ongoing commitment to developing novel drug delivery systems.